{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:13:55Z","timestamp":1793060035422,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Else-Kr\u00f6ner-Fresenius-Stiftung","award":["NAKSYS\u2013 016_Kolleg.03"],"award-info":[{"award-number":["NAKSYS\u2013 016_Kolleg.03"]}]},{"name":"Research Commission of the Faculty of Medicine, University of Freiburg","award":["MZ"],"award-info":[{"award-number":["MZ"]}]},{"name":"Albert-Ludwigs-Universit\u00e4t Freiburg im Breisgau"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hepatitis E virus (HEV) infection is a frequent cause of acute viral hepatitis. Immunocompromised patients are at increased risk for viral infection and chronic courses of hepatitis. Whether patients with autoimmune diseases are at risk of developing clinically relevant hepatitis or even chronic liver disease after HEV infection is discussed controversially. ANCA-associated vasculitis is a rare autoimmune disease with potentially life-threatening organ involvement, thus requiring intensive immunosuppression with glucocorticoids, cyclophosphamide, or rituximab. As there are no reports available on the infection with HEV in patients with ANCA-associated vasculitis, clinical decision making in such cases is based on experiences from other disease entities. Therefore, in this study we analyzed the course of liver disease and the therapeutic management of autoimmune vasculitis in a retrospective cohort of five patients with ANCA-associated vasculitis and acute hepatitis E.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Four patients were on immunosuppressive maintenance therapy and one patient was on remission induction therapy with cyclophosphamide and high dose glucocorticoids. All patients had at least one potentially hepatotoxic co-medication at the time of hepatitis. Hepatitis-associated clinical symptoms were recorded in four of five patients. The course of hepatitis was characterized by strongly elevated transaminases, a temporary liver failure was observed in one case. The management of hepatitis E included cessation of the immunosuppressants in all patients, whereas oral glucocorticoids were not discontinued. Under this regime, all patients cleared the virus without additional anti-viral treatment. Liver enzymes normalized one month after they peaked. In the follow-up period of at least 1.5\u00a0years (range 1.5\u201312\u00a0years), no chronic liver disease was observed, although one patient died of cholangiocarcinoma with liver metastases some years after HEV infection. Vasculitis was not active in our patient cohort at the time of HEV infection. However, inflammatory flares occured in three of five patients after discontinuation of the immunosuppressive therapy. Immunosuppressants were paused for a median time of 4\u00a0weeks and after their resumption vasculitic disease activity was controlled in all patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Acute HEV infection in patients with ANCA-associated vasculitis shows a favorable outcome of liver disease but bears the risk of inflammatory flares due to cessation of immunosuppression.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02586-1","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T12:04:14Z","timestamp":1670933054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Favourable outcome of acute hepatitis E infection in patients with ANCA-associated vasculitis"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5575-0787","authenticated-orcid":false,"given":"Markus","family":"Zeisbrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Wendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Finzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard E.","family":"Voll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Venhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"issue":"1","key":"2586_CR1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jhep.2016.02.045","volume":"65","author":"Y Debing","year":"2016","unstructured":"Debing Y, Moradpour D, Neyts J, Gouttenoire J. Update on hepatitis E virology: implications for clinical practice. J Hepatol. 2016;65(1):200\u201312.","journal-title":"J Hepatol"},{"issue":"13","key":"2586_CR2","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1056\/NEJMra1204512","volume":"367","author":"JH Hoofnagle","year":"2012","unstructured":"Hoofnagle JH, Nelson KE, Purcell RH. Hepatitis E. N Engl J Med. 2012;367(13):1237\u201344.","journal-title":"N Engl J Med"},{"issue":"10","key":"2586_CR3","doi-asserted-by":"publisher","first-page":"25711","DOI":"10.3390\/ijms161025711","volume":"16","author":"D Lapa","year":"2015","unstructured":"Lapa D, Capobianchi MR, Garbuglia AR. Epidemiology of hepatitis E virus in European countries. Int J Mol Sci. 2015;16(10):25711\u201343.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2586_CR4","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa0706992","volume":"358","author":"N Kamar","year":"2008","unstructured":"Kamar N, Selves J, Mansuy JM, Ouezzani L, Peron JM, Guitard J, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008;358(8):811\u20137.","journal-title":"N Engl J Med"},{"key":"2586_CR5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ijid.2019.11.014","volume":"91","author":"LH Harritshoj","year":"2020","unstructured":"Harritshoj LH, Hother CE, Sengelov H, Daugaard G, Sorensen SS, Jacobsen S, et al. Epidemiology of hepatitis E virus infection in a cohort of 4023 immunocompromised patients. Int J Infect Dis. 2020;91:188\u201395.","journal-title":"Int J Infect Dis"},{"issue":"2","key":"2586_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jcv.2010.06.016","volume":"49","author":"S Tavitian","year":"2010","unstructured":"Tavitian S, Peron JM, Huynh A, Mansuy JM, Ysebaert L, Huguet F, et al. Hepatitis E virus excretion can be prolonged in patients with hematological malignancies. J Clin Virol. 2010;49(2):141\u20134.","journal-title":"J Clin Virol"},{"issue":"14","key":"2586_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000675","volume":"94","author":"H Bauer","year":"2015","unstructured":"Bauer H, Luxembourger C, Gottenberg JE, Fournier S, Abravanel F, Cantagrel A, et al. Outcome of hepatitis E virus infection in patients with inflammatory arthritides treated with immunosuppressants: a French retrospective multicenter study. Medicine (Baltimore). 2015;94(14): e675.","journal-title":"Medicine (Baltimore)"},{"key":"2586_CR8","doi-asserted-by":"crossref","unstructured":"Honer zu Siederdissen C, Pischke S, Schlue J, Deterding K, Hellms T, Schuler-Luttmann S, et al. Chronic hepatitis E virus infection beyond transplantation or human immunodeficiency virus infection. Hepatology. 2014;60(3):1112\u20133.","DOI":"10.1002\/hep.26987"},{"key":"2586_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s41927-020-00149-0","volume":"4","author":"S Di Bartolomeo","year":"2020","unstructured":"Di Bartolomeo S, Carubbi F, Cipriani P. Hepatitis E Virus and rheumatic diseases: what do rheumatologists need to know? BMC Rheumatol. 2020;4:51.","journal-title":"BMC Rheumatol"},{"key":"2586_CR10","doi-asserted-by":"crossref","unstructured":"Pischke S, Peron JM, von Wulffen M, von Felden J, Honer Zu Siederdissen C, Fournier S, et al. Chronic hepatitis E in rheumatology and internal medicine patients: a retrospective multicenter European cohort study. Viruses. 2019;11(2).","DOI":"10.3390\/v11020186"},{"key":"2586_CR11","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.3389\/fimmu.2019.02617","volume":"10","author":"M Akiyama","year":"2019","unstructured":"Akiyama M, Zeisbrich M, Ibrahim N, Ohtsuki S, Berry GJ, Hwang PH, et al. Neutrophil extracellular traps induce tissue-invasive monocytes in granulomatosis with polyangiitis. Front Immunol. 2019;10:2617.","journal-title":"Front Immunol"},{"key":"2586_CR12","doi-asserted-by":"crossref","unstructured":"Guo Z, Zhang Z, Prajapati M, Li Y. Lymphopenia caused by virus infections and the mechanisms beyond. Viruses. 2021;13(9).","DOI":"10.3390\/v13091876"},{"issue":"19","key":"2586_CR13","doi-asserted-by":"publisher","first-page":"5721","DOI":"10.3748\/wjg.v20.i19.5721","volume":"20","author":"HB Zhou","year":"2014","unstructured":"Zhou HB, Hu JY, Hu HP. Hepatitis B virus infection and intrahepatic cholangiocarcinoma. World J Gastroenterol. 2014;20(19):5721\u20139.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"2586_CR14","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.ajpath.2019.01.018","volume":"189","author":"MC Navas","year":"2019","unstructured":"Navas MC, Glaser S, Dhruv H, Celinski S, Alpini G, Meng F. Hepatitis C virus infection and cholangiocarcinoma: an insight into epidemiologic evidences and hypothetical mechanisms of oncogenesis. Am J Pathol. 2019;189(6):1122\u201332.","journal-title":"Am J Pathol"},{"key":"2586_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ijid.2017.08.010","volume":"64","author":"M Amougou Atsama","year":"2017","unstructured":"Amougou Atsama M, Atangana PJA, Noah Noah D, Moundipa PF, Pineau P, Njouom R. Hepatitis E virus infection as a promoting factor for hepatocellular carcinoma in Cameroon: preliminary observations. Int J Infect Dis. 2017;64:4\u20138.","journal-title":"Int J Infect Dis"},{"key":"2586_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ijid.2018.04.003","volume":"71","author":"MJ Bai","year":"2018","unstructured":"Bai MJ, Zhou N, Dong W, Li GX, Cong W, Zhu XQ. Seroprevalence and risk factors of hepatitis E virus infection in cancer patients in eastern China. Int J Infect Dis. 2018;71:42\u20137.","journal-title":"Int J Infect Dis"},{"issue":"10","key":"2586_CR17","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1111\/liv.14137","volume":"39","author":"A Beer","year":"2019","unstructured":"Beer A, Holzmann H, Pischke S, Behrendt P, Wrba F, Schlue J, et al. Chronic Hepatitis E is associated with cholangitis. Liver Int. 2019;39(10):1876\u201383.","journal-title":"Liver Int"},{"key":"2586_CR18","doi-asserted-by":"crossref","unstructured":"Hartl J, Otto B, Madden RG, Webb G, Woolson KL, Kriston L, et al. Hepatitis E Seroprevalence in Europe: A Meta-Analysis. Viruses. 2016;8(8).","DOI":"10.3390\/v8080211"},{"issue":"3","key":"2586_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/annrheumdis-2021-221794","volume":"81","author":"PC Grayson","year":"2022","unstructured":"Grayson PC, Ponte C, Suppiah R, Robson JC, Craven A, Judge A, et al. 2022 American College of Rheumatology\/European alliance of associations for rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81(3):309\u201314.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2586_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1136\/annrheumdis-2021-221795","volume":"81","author":"JC Robson","year":"2022","unstructured":"Robson JC, Grayson PC, Ponte C, Suppiah R, Craven A, Judge A, et al. 2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81(3):315\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"2586_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00393-017-0394-1","volume":"76","author":"JH Schirmer","year":"2017","unstructured":"Schirmer JH, Aries PM, de Groot K, Hellmich B, Holle JU, Kneitz C, et al. S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis. Z Rheumatol. 2017;76(Suppl 3):77\u2013104.","journal-title":"Z Rheumatol"},{"issue":"9","key":"2586_CR22","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","volume":"75","author":"M Yates","year":"2016","unstructured":"Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583\u201394.","journal-title":"Ann Rheum Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02586-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02586-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02586-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T12:11:55Z","timestamp":1670933515000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02586-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2586"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02586-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"assertion":[{"value":"9 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of the University of Freiburg Medical School. Written informed consent was obtained from patients. It was not possible to get written informed consent from two deceased patients. As patient cases have been analyzed anonymously, this proceeding is usual for retrospective anonymous cohorts and was approved by the local Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patients agreed to have their non-identifiable information used for research and publishing.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"433"}}